An award-winning researcher in the field of gynecological cancer, Dr. Anil Sood has published many peer-reviewed papers. Vice chair for translational research in the department of gynecologic oncology at The University of Texas’s MD Anderson Cancer Center, Dr. Anil Sood leverages his expertise to support the work of the Foundation for Women’s Cancer, which collaborates with NRG Oncology to encourage clinical trial participation.
Before a new treatment can receive approval from the US Food and Drug Administration, it must pass through a number of clinical trials to ensure its efficacy and safety. Clinical trials are among the final steps in the development of a drug, which must show both promise and safety before the developer can call for human participants.
Those who choose to participate in a clinical trial receive access to new treatments not yet available to the general public. For women who have treatment-resistant or recurrence of a cancer, this may mean new hope when conventional methods have failed to get results.
Participants in clinical trials receive attentive care. The research team closely monitors the health of the participant and is proactive in managing any side effects, since part of the purpose of a clinical trial is to determine how the body will respond to treatment.
Clinical trials also offer participants the opportunity to contribute to the advancement of cancer care. Regardless of the study’s outcome, physicians ultimately will have more tools and knowledge to help diagnosed patients in the future.